Publications by authors named "Kathrin Haberecht"
Assessing the Use of BotulinumtoxinA for Hyperactive Urinary Tract Dysfunction a Decade After Approval: General Versus Local Anesthesia for BotulinumtoxinA Detrusor Injection.
Heinrich Schulte-Baukloh Apostolos Apostolidis Catarina Weiss Thorsten Schlomm Sarah Weinberger Kathrin Haberecht
Toxins (Basel)
October 2024
Article Synopsis
- OnabotulinumtoxinA detrusor injection (OnabotA DI) is a treatment for patients with overactive bladder issues that was approved 10 years ago, often performed under local anesthesia (LA) or general anesthesia (GA).
- In a study of 104 patients, those under LA reported higher anxiety and pain compared to those under GA, particularly during the first injection, but surprisingly still preferred LA despite these concerns.
- The findings highlighted a notable decrease in anxiety for repeat injections with LA, suggesting that familiarity with the procedure could ease patient anxiety over time, even though pain was significantly lower with GA.
Assessing the Use of BotulinumtoxinA for Hyperactive Urinary Tract Dysfunction a Decade after Approval: A Single-Blind Study to Evaluate the Reduction in Pain in OnabotulinumtoxinA Detrusor Injection Using Different Injection Needles.
Heinrich Schulte-Baukloh Catarina Weiss Thorsten Schlomm Sarah Weinberger Hendrik Borgmann Kathrin Haberecht
Toxins (Basel)
September 2024
Overactive bladder (OAB) has a significant impact on the quality of life; thus, it requires treatment that can be adhered to over a long period without undue side effects. The current treatment which uses an anticholinergic or β-3 agonist may fail to improve symptoms and has side effects, leading to high discontinuation rates. OnabotulinumtoxinA (OnabotA) detrusor injection has been approved for idiopathic OAB as a second-line treatment with good effectiveness and tolerability.
View Article and Find Full Text PDF